English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

METHODS: In our investigator driven, prospective, randomized, open label clinical trial with blinded endpoint assessment we randomly assigned ADPKD patients, 18-60 years of age and an with estimated glomerular filtration rate (eGFR) 30-60 mL/min/ 1.73m, to either lanreotide treatment (120 mg sc once every 4 weeks) on top of standard care or to standard care only. The primary outcome was annual change in eGFR assessed as slope through eGFR values during the 2.5 year treatment phase. Secondary outcomes were change in eGFR, height adjusted Total Kidney Volume (hTKV, assessed by MRI) and Quality of Life (QoL) 12 weeks after the end-of-treatment visit compared to pretreatment, and incidence of worsening kidney function (defined as sustained 30% decline in eGFR or start of dialysis or transplantation).

LB04RENOPROTECTIVE EFFICACY AND SAFETY OF THE SOMATOSTATIN ANALOGUE LANREOTIDE IN LATER STAGE ADPKD